Biomarkers Across Neurodegenerative Disease
The Michael J. Fox Foundation for Parkinson¹s Research (MJFF), the Alzheimer¹s Association (ALZ),and The W. Garfield Weston Foundation announce a collaborative Request for Applications (RFA) to stimulate collaborative analyses across the Alzheimer¹s disease (AD) and Parkinson¹s disease (PD) research enterprises to engage in further data analysis of existing cohorts, including, but not limited to, biomarker discovery, standardization of assays, genetic profiles, and imaging modalities. The RFA aims to build on the existing momentum to leverage similar activities and increase impact across the neurodegenerative disease spectrum. It also builds on recent evidence suggesting substantial overlap between AD, PD, and other neurodegenerative diseases pathologically, but also potentially biologically. The RFA is designed to enable preliminary pilot research or proof-of-principle studies utilizing data and/or samples from two large biomarker studies, the Alzheimer¹s Disease Neuroimaging Initiative (ADNI) and the Parkinson¹s Progression Markers Initiative (PPMI), in order to garner further research support from other funding agencies.
MJFF, ALZ and The Weston Foundation anticipate funding multiple awards under this program. Applicants may request up to two years and $150,000 in total costs, inclusive of both direct and indirect costs. Exceptions for particularly unique projects or projects that span the globe will be considered, but requests that exceed $150,000 must be well justified. Indirect costs may not exceed 10% of direct costs. Please note that rent for laboratory/office space is expected to be covered by indirect costs paid to the institution.
IMPORTANT DEADLINES AND DATES:
- March 19, 2014 Letters of intent due
- April 2, 2014 Full applications invited
- May 14, 2014 Full applications due
For more information, visit: